Matrix metalloproteinase responsive hydrogel microplates for programmed killing of invasive tumour cells
- PMID: 38013908
- PMCID: PMC10540463
- DOI: 10.1039/d3lp00057e
Matrix metalloproteinase responsive hydrogel microplates for programmed killing of invasive tumour cells
Abstract
Interactive materials are an emerging class of systems that can offer control over response and adaptivity in polymer structures towards the meso- and macroscale. Here, we use enzyme regulated cleavage of peptide crosslinkers in polymer hydrogels to release a cytotoxic therapeutic nanoparticle with an adaptable mechanism. Hydrogel microplates were formed through polyethylene glycol/peptide photoinitiated thiol-ene chemistry in a soft-lithography process to give square plates of 20 by 20 μm with a height of 10 μm. The peptide was chosen to be degradable in the presence of matrix metalloproteinase 2/9 (MMP-2/9). The hydrogel material's mechanical properties, swelling, and protease degradation were characterised. The microfabricated hydrogels were loaded with docetaxel (DTXL) containing poly(dl-lactide-co-glycolide) (PLGA) nanoparticles, and characterised for enzyme responsivity, and toxicity to MMP-2/9 overexpressing brain cancer cell line U87-MG. A 5-fold decrease in EC50 was seen compared to free DTXL, and a 20-fold decrease was seen for the MMP responsive microplates versus a non-degradable control microplate. Potential applications of this system in post-resection glioblastoma treatment are envisioned.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
There are no conflicts to declare.
Figures
References
-
- Tamimi A. F. and Juweid M., Epidemiology and Outcome of Glioblastoma, in Glioblastoma, ed. S. De Vleeschouwer, Codon Publications, Brisbane (AU), 2017 - PubMed
-
- Stupp R. Mason W. P. van den Bent M. J. Weller M. Fisher B. Taphoorn M. J. B. Belanger K. Brandes A. A. Marosi C. Bogdahn U. Curschmann J. Janzer R. C. Ludwin S. K. Gorlia T. Allgeier A. Lacombe D. Cairncross J. G. Eisenhauer E. Mirimanoff R. O. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330. doi: 10.1056/NEJMoa043330. - DOI - PubMed
LinkOut - more resources
Full Text Sources